Acadian Asset Management
CYTH

Acadian Asset Management’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Acadian Asset Management’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,527
Closed -$35K – 1827
2023
Q4 		$35K Buy
+2,527
New +$3.22K ﹤0.01% 1509

Other funds holding CYTH

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Acadian Asset Management's CYTH Position: Q1 2024 in Review

Acadian Asset Management sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2024, closing a stake of 2,527 shares — an estimated $35K sold.

Acadian Asset Management first reported a position in CYTH in Q4 2023 and held it in 1 quarter. The position peaked at $35K in Q4 2023. 22 funds tracked by Wall St. Rank hold CYTH as of Q1 2024.

  • Acadian Asset Management reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Acadian Asset Management sold 2,527 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $35K.
  • Acadian Asset Management first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Acadian Asset Management's Cyclo Therapeutics, Inc. Common Stock position peaked at $35K in Q4 2023.
  • 22 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Acadian Asset Management's 13F filing for Q1 2024, filed 10 May 2024.